ArticleBlood advances2020

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.

Andrew Kent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.